Deferred Income Tax Assets, Net in USD of ELITE PHARMACEUTICALS INC /NV/ from Q1 2022 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Deferred Income Tax Assets, Net history and change rate from Q1 2022 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Deferred Income Tax Assets, Net for the quarter ending 30 Sep 2025 was $11,804,166.000, a 43.4% decline year-over-year.
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Deferred Income Tax Assets, Net (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $11,804,166 -$9,039,338 -43.4% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $13,481,213 -$8,661,473 -39.1% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $18,365,748 -$3,795,147 -17.1% 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 $20,689,381 +$455,778 +2.3% 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $20,843,504 +$1,410,336 +7.3% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $22,142,686 +$19,970,865 +9.2% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $22,160,895 +$19,989,074 +9.2% 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $20,233,603 +$18,061,782 +8.3% 31 Dec 2023 10-Q 14 Feb 2024
Q3 2023 $19,433,168 +$17,261,347 +7.9% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $2,171,821 $0 0% 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 $2,171,821 $0 0% 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $2,171,821 31 Dec 2022 10-Q 14 Feb 2023
Q3 2022 $2,171,821 30 Sep 2022 10-Q 14 Nov 2022
Q2 2022 $2,171,821 30 Jun 2022 10-Q 15 Aug 2022
Q1 2022 $2,171,821 31 Mar 2022 10-K 29 Jun 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.